DOCSLIB.ORG

Subject Index Proc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Subject Index Proc. Natl. Acad. Sci. USA 87 (1990) 10129 Guanine adduct Purification of a factor capable of stimulating the guanine nucleotide Acetylaminofluorene bound to different guanines of the sequence exchange reaction of ras proteins and its effect on ras-related small -GGCGCC- is excised with different efficiencies by the UvrABC molecular mass G proteins, 8008 excision nuclease in a pattern not correlated to the potency of mutation Posttranslationally processed structure of the human platelet protein smg induction, 191 p21B: Evidence for geranylgeranylation and carboxyl methylation of the C-terminal cysteine, 8960 Guanine nucleotide binding Increased conversion of phosphatidylinositol to phosphatidylinositol a-Tubulin influences nucleotide binding to ,-tubulin: An assay using phosphate in Dictyostelium cells expressing a mutated ras gene, 9197 picomoles of unpurified protein, 5041 Molecular cloning of the gene for the human placental GTP-binding Guanine nucleotide-binding protein, l00-kDa protein Gp (G25K): Identification of this GTP-binding protein as the Microsomal and cytosolic fractions of guinea pig hepatocytes contain human homolog of the yeast cell-division-cycle protein CDC42, 9853 100-kilodalton GTP-binding proteins reactive with antisera against a Guanine nucleotide-exchange factor subunits of stimulatory and inhibitory heterotrimeric GTP-binding Central.prolactin infusions stimulate maternal behavior in steroid-treated, proteins, 6321 nulliparous female rats, 8003 Guanine nucleotide-binding protein, heterotrimeric Guanine nucleotide-exchange promoter REP Myristoylation of an inhibitory GTP-binding protein a subunit is essential Identification of a nucleotide exchange-promoting activity for p2l'", 5998 for its membrane attachment, 568 G-protein a-subunit expression, myristoylation, and membrane Guanosine 3'-diphosphate 5'-diphosphate association in COS cells, 728 Guanosine 3'-diphosphate 5'-diphosphate is not required for growth Isoproterenol stimulates shift of G proteins from plasma membrane to rate-dependent control of rRNA synthesis in Escherichia coli, 5533 pinocytotic vesicles in rat adipocytes: A possible means of signal Guard cell dissemination, 1208 Repetitive increases in cytosolic Ca2" of guard cells by abscisic acid Molecular cloning of ,3 subunit, a third form of the G protein a-subunit activation of nonselective Ca2" permeable channels, 9305 polypeptide, 2329 Regions of the a1-adrenergic receptor involved in coupling to Guaymi Indians phosphatidylinositol hydrolysis and enhanced sensitivity of biological Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians function, 28% in Panama, 8840 Involvement of GTP-binding proteins in actin polymerization in human Guinea pig neutrophils, 2921 Immunological evidence for the accumulation of lipoprotein(a) in the RTA, a candidate G protein-coupled receptor: Cloning, sequencing, and atherosclerotic lesion of the hypoascorbemic guinea pig, 9388 tissue distribution, 3052 Molecular characterization of a rat a2B-adrenergic receptor, 3102 Gynogenesis 2-Azido-[32PJNAD', a photoactivatable probe for G-protein structure: Genetic variation in clonal vertebrates detected by simple-sequence DNA Evidence for holotransducin oligomers in which the ADP-ribosylated fingerprinting, 5653 carboxyl terminus of a interacts with both a and y subunits, 3645 gypsy element Molecular cloning and characterization of GPAI, a G protein a subunit Potentiation of a polyadenylylation site by a downstream protein-DNA gene from Arabidopsis thaliana, 3821 4373 f3 and y subunits of a yeast guanine nucleotide-binding protein are not interaction, essential for membrane association of the a subunit but are required Gypsy moth for receptor coupling, 4363 See Lymantria Membrane localization of the pertussis toxin-sensitive G-protein subunits ai-2 and ai-3 and expression of a metallothionein-a2 fusion gene in H-2 LLC-PK, cells, 4635 See Major histocompatibility complex, mouse Evidence that a guanine nucleotide-binding protein linked to a muscarinic HA-966 receptor inhibits directly phospholipase C, 4889 See 3-Amino-1-hydroxypyrrolid-2-one Brain G protein y subunits contain an all-trans-geranylgeranylcysteine methyl ester at their carboxyl termini, 5868 Habituation G protein y subunits contain a 20-carbon isoprenoid, 5873 Habituation in the single cell: Diminished secretion of norepinephrine Octyl glucoside extracts GTP-binding regulatory proteins from rat brain with repetitive depolarization of PC12 cells, 2031 "synaptoneurosomes" as large, polydisperse structures devoid of Py complexes and sensitive to disaggregation by guanine nucleotides, 6413 Haentanthus ktherinae. Alternative splicing produces transcripts encoding two forms of the a Autoantibodies from a patient with scleroderma CREST recognize subunit of GTP-binding protein G., 6477 kinetochores of the higher plant Haemanthus, 3599 Membrane localization of the pertussis toxin-sensitive G-protein subunits Incorporation of Paramecium axonemal tubulin into higher plant cells ai-2 and a-3 and expression of a metallothionein-a2 fusion gene in reveals functional sites of microtubule assembly, 8825 LLC-PKj cells (Correction), 7344 Hair Proximal tubular epithelial cells possess a novel 42-kilodalton guanine Hair-specific expression of chloramphenicol acetyltransferase in nucleotide-binding regulatory protein, 7532 transgenic mice under the control of an ultra-high-sulfur keratin The y subunit of transducin is farnesylated, 7673 promoter, 6848 G protein diversity is increased by associations with a variety of y subunits, 7973 Hair cell Mutations of the G, a-subunit gene in Albright hereditary osteodystrophy Actin cores of hair-cell stereocilia support myosin motility, 8627 detected by denaturing gradient gel electrophoresis, 8287 G protein diversity: A distinct class of a subunits is present in Haliotis vertebrates and invertebrates, 9113 Species-specific sequences of abalone lysin, the sperm protein that creates a hole in the egg envelope, 5792 Guanine nucleotide-binding protein, small See also Ras protein Halobacterinum halobium GTP-binding Yptl protein and Ca2+ function independently in a cell-free Transformation of Halobacterium halobium: Development of vectors and protein transport reaction, 355 investigation of gas vesicle synthesis, 6772 Thrombolamban, the 22-kDa platelet substrate of cyclic AMP-dependent Thickness determination of biological samples with a z-calibrated protein kinase, is immunologically homologous with the Ras family of scanning tunneling microscope, 9343 GTP-binding proteins, 758 Haloferax volcanii ADP-ribosylation factor is functionally and physically associated with the Genes for tryptophan biosynthesis in the archaebacterium Haloferax Golgi complex, 1238 6614 Subcellular distribution of small GTP binding proteins in pancreas: volcanii, Identification of small GTP binding proteins in the rough endoplasmic Transformation of Halobacterium halobium: Development of vectors and reticulum, 12% investigation of gas vesicle synthesis, 6772 rab3 is a small GTP-binding protein exclusively localized to synaptic Haloperidol vesicles, 1988 Structure-based design of nonpeptide inhibitors specific for the human Selective amplification of an mRNA and related pseudogene for a human immunodeficiency virus 1 protease, 6644 ADP-ribosylation factor, a guanine nucleotide-dependent protein activator of cholera toxin 2206 Halothane Hydrolysis of GTP by p21NkAS, the NRAS protooncogene product, is Subcellular distribution of an inhalational anesthetic in situ, 454 accompanied by a conformational change in the wild-type protein: Use A genetic study of the anesthetic response: Mutants of Drosophila of a single fluorescent probe at the catalytic site, 3562 melanogaster altered in sensitivity to halothane, 8632 Crystal structure of an active form of RAS protein, a complex of a GTP analog and the HRAS p21 catalytic domain, 4849 Hammerhead RNA Association of the GTP-binding protein Rab3A with bovine adrenal Substrate sequence effects on "hammerhead" RNA catalytic efficiency, chromaffin granules, 5692 1668 Platelet-derived growth factor stimulates formation of active p21's GTP Hamster cell line complex in Swiss mouse 3T3 cells, 5993 Hamster cell line suitable for transfection assay of transforming genes, Identification of a nucleotide exchange-promoting activity for p2l", 5998 2409 RAP2B: A RAS-related GTP-binding protein from platelets, 6527 GTP-binding proteins in rat liver nuclear envelopes, 7080 H antigen Accumulation of p21"-GTP in response to stimulation with epidermal Molecular cloning, sequence, and expression of a human growth factor and oncogene products with tyrosine kinase activity, GDP-L-fucose:fi-D-galactoside 2-a-L-fucosyltransferase cDNA that can 7926 form the H blood group antigen, 6674 10130 Subject Index Proc. Natl. Acad. Sci. USA 87 (1990) Haplotype HeLa cell nuclear protein Haplotype of multiple polymorphisms resolved by enzymatic Identification and characterization of a HeLa nuclear protein that amplification of single DNA molecules, 62% specifically binds to the trans-activation-response (TAR) element of human HAP2 protein immunodeficiency virus, 3624 The B subunit of a rat heteromeric CCAAT-binding transcription factor Helianthus shows a striking sequence identity with the yeast Hap2 transcription Helianthus annuus ssp. texanus has chloroplast DNA and nuclear factor, 5378 ribosomal RNA genes of Helianthus debilis ssp. cucumerifolius, 593 Hapten a-Helical coiled coil Antibody caging of a nuclear-targeting signal,
Recommended publications
  • A Synopsis of Phaseoleae (Leguminosae, Papilionoideae) James Andrew Lackey Iowa State University

    A Synopsis of Phaseoleae (Leguminosae, Papilionoideae) James Andrew Lackey Iowa State University

    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1977 A synopsis of Phaseoleae (Leguminosae, Papilionoideae) James Andrew Lackey Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Botany Commons Recommended Citation Lackey, James Andrew, "A synopsis of Phaseoleae (Leguminosae, Papilionoideae) " (1977). Retrospective Theses and Dissertations. 5832. https://lib.dr.iastate.edu/rtd/5832 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This material was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1.The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image.
  • Final Report Template

    Final Report Template

    Native Legumes as a Grain Crop for Diversification in Australia RIRDC Publication No. 10/223 RIRDCInnovation for rural Australia Native Legumes as a Grain Crop for Diversification in Australia by Megan Ryan, Lindsay Bell, Richard Bennett, Margaret Collins and Heather Clarke October 2011 RIRDC Publication No. 10/223 RIRDC Project No. PRJ-000356 © 2011 Rural Industries Research and Development Corporation. All rights reserved. ISBN 978-1-74254-188-4 ISSN 1440-6845 Native Legumes as a Grain Crop for Diversification in Australia Publication No. 10/223 Project No. PRJ-000356 The information contained in this publication is intended for general use to assist public knowledge and discussion and to help improve the development of sustainable regions. You must not rely on any information contained in this publication without taking specialist advice relevant to your particular circumstances. While reasonable care has been taken in preparing this publication to ensure that information is true and correct, the Commonwealth of Australia gives no assurance as to the accuracy of any information in this publication. The Commonwealth of Australia, the Rural Industries Research and Development Corporation (RIRDC), the authors or contributors expressly disclaim, to the maximum extent permitted by law, all responsibility and liability to any person, arising directly or indirectly from any act or omission, or for any consequences of any such act or omission, made in reliance on the contents of this publication, whether or not caused by any negligence on the part of the Commonwealth of Australia, RIRDC, the authors or contributors. The Commonwealth of Australia does not necessarily endorse the views in this publication.
  • Allopolyploidy and Root Nodule Symbiosis in Glycine

    Allopolyploidy and Root Nodule Symbiosis in Glycine

    TWO TO TANGO: ALLOPOLYPLOIDY AND ROOT NODULE SYMBIOSIS IN GLYCINE SUBGENUS GLYCINE A Dissertation Presented to the Faculty of the Graduate School of Cornell University in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Adrian Federico Powell January 2017 © 2017 Adrian Federico Powell TWO TO TANGO: ALLOPOLYPLOIDY AND ROOT NODULE SYMBIOSIS IN GLYCINE SUBGENUS GLYCINE Adrian Federico Powell, Ph.D. Cornell University 2017 Polyploidy (or whole genome duplication) and root nodule symbioses with bacteria (termed ‘rhizobia’) have both been important phenomena in the evolutionary history of the legume family (Leguminosae). Recently, it has been proposed that polyploidy may have played a critical role in the development or refinement of nodulation. Given the varied potential impacts of polyploidy, effects on biotic interactions are plausible. However, direct studies of the interactions between these phenomena in symbiotic, nodule-forming species are lacking. In this dissertation, using a complex of recently formed allopolyploids in Glycine subgenus Glycine, the perennial relatives of soybean, we examined (1) the root metabolites and symbiotic signaling capacity of multiple allopolyploid species relative to the diploid progenitor species that hybridized to form each allopolyploid, (2) the nodulation-related responses of allopolyploids and diploid progenitors to rhizobia and (3) the transcriptome-level responses to inoculation in allopolyploid G. dolichocarpa (T2) and its diploid progenitors. These objectives were pursued using a variety of approaches including root metabolite profiling, inoculation trials, and RNA sequencing. We found that, while there were no common transgressive patterns in the root metabolite profiles of allopolyploids in the complex, one of the progenitors of T2 had distinctive root metabolite and exudate profiles; profiles of symbiotic signaling metabolites were also altered in the allopolyploid.
  • An Overview of Lesch-Nyhan Syndrome

    An Overview of Lesch-Nyhan Syndrome

    An Overview of Lesch-Nyhan Syndrome Abstract Lesch-Nyhan Syndrome is a disorder that strikes the sufferer with debilitating motor and cognitive problems, hyperuricemia, and the urge to do harm to yourself with acts of self-injurious behavior. Research has lead to the discovery of a genetic sequence that results in a defective enzyme, but researchers are still unsure how this leads to the neurological and behavioral problems that are the hallmark of the disorder. Treatments as simple as wearing oven mitts and as complicated as electrical wiring in the brain have been used to help LNS patients, but no cure for the syndrome seems in sight. Lars Sorensen Prof. Stanley Vitello : IDD : 293:522 : Fall 2008 Rutgers University - Graduate School of Education Introduction In the world of developmental and physical disorders none is stranger than Lesch-Nyhan Syndrome. It brings with it a variety of physical ailments but the defining feature of the condition is behavioral. The sufferer seems to be overtaken with an involuntary uncontrollable compulsion to destroy themselves and those around them. In the autumn of 1962, a young mother brought her four year old son to the pediatric emergency room at Johns Hopkins medical center. The boy had previously been diagnosed with cerebral palsy and could not walk or sit up. He was experiencing pain when he urinated. His mother told the resident who was examining the boy that he had “sand in his diaper” (Preston, 2007). The young boy was admitted to the hospital. The resident and an intern began examining the “sand” from the boy's diaper.
  • (Hunter Syndrome) Complicated by Autoimmune Hemolytic Anemia

    (Hunter Syndrome) Complicated by Autoimmune Hemolytic Anemia

    Bone Marrow Transplantation (2000) 25, 1093–1099 2000 Macmillan Publishers Ltd All rights reserved 0268–3369/00 $15.00 www.nature.com/bmt Case report Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia CA Mullen1,2, JN Thompson3, LA Richard and KW Chan1 Departments of 1Pediatrics and 2Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas; 3Laboratory of Medical Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA Summary: a median of 21 years in type IIB.8 Allogeneic BMT has been used to treat Hunter disease, but remains controversial This report describes unrelated umbilical cord blood since it often fails to reverse CNS impairment9–11 and car- transplantation for a 10-month-old infant boy with ries with it substantial early mortality and morbidity. Here, mucopolysaccharidosis IIB (Hunter syndrome), an X- we report treatment of an infant with mucopolysacch- linked metabolic storage disorder due to deficiency of arisosis type IIB with transplantation of unrelated umbilical iduronate sulfatase. Two years after transplant ෂ55% cord blood cells and its complication by autoimmune hemo- normal plasma enzyme activity has been restored and lytic anemia. abnormal urinary excretion of glycosaminoglycans has nearly completely resolved. The boy has exhibited nor- mal growth and development after transplant. Nine Case report months after transplant he developed severe auto- immune hemolytic anemia and required 14 months of The patient is the only child of a couple with a maternal corticosteroid treatment to prevent clinically significant family history of Hunter syndrome. The mother’s brother anemia. Bone marrow transplantation for Hunter syn- was diagnosed with Hunter syndrome in 1979 at age 3 years drome and post-transplant hemolytic anemia are when he exhibited the physical stigmata of the disorder.
  • Mini-Review on “Molecular Diagnosis of 65 Families With

    Mini-Review on “Molecular Diagnosis of 65 Families With

    Mashima R, Okuyama T. J Rare Dis Res Treat. (2016) 2(1): 43-46 Journal of www.rarediseasesjournal.com Rare Diseases Research & Treatment Mini-Review Open Access Mini-review on “Molecular diagnosis of 65 families with mucopoly- saccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural stud- ies on iduronate-2-sulfatase.” Ryuichi Mashima1* and Torayuki Okuyama1,2 1Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan 2Center for Lysosomal Storage Disorders, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan ABSTRACT Article Info Article Notes Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM #309900) Received: November 29, 2016 is an X-linked congenital disorder characterized by an accumulation of Accepted: December 28, 2016 glycosaminoglycans in the body. Accumulating evidence has suggested that the prevalence of the severe type of MPS II is almost 70%. In addition, novel *Correspondence: mutations that are relevant to MPS II pathogenesis are being increasingly Ryuichi Mashima, Department of Clinical Laboratory Medicine, National Center for Child Health and Development, 2-10- discovered, so the databases of genetic data regarding pathogenic mutations 1 Okura, Setagaya-ku, Tokyo 157-8535, Japan, E-mail: have been growing. We have recently reported a collection of 16 novel [email protected] pathogenic mutations of the iduronate-2-sulfatase (IDS) gene in 65 families with MPS II in a Japanese population1. We also proposed that a homology- © 2016 Ryuichi Mashima.
  • Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment

    Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment

    International Journal of Molecular Sciences Review Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment Francesca D’Avanzo 1,2 , Laura Rigon 2,3 , Alessandra Zanetti 1,2 and Rosella Tomanin 1,2,* 1 Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women’s and Children ‘s Health, University of Padova, Via Giustiniani 3, 35128 Padova, Italy; [email protected] (F.D.); [email protected] (A.Z.) 2 Fondazione Istituto di Ricerca Pediatrica “Città della Speranza”, Corso Stati Uniti 4, 35127 Padova, Italy; [email protected] 3 Molecular Developmental Biology, Life & Medical Science Institute (LIMES), University of Bonn, 53115 Bonn, Germany * Correspondence: [email protected] Received: 17 January 2020; Accepted: 11 February 2020; Published: 13 February 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) was first described by Dr. Charles Hunter in 1917. Since then, about one hundred years have passed and Hunter syndrome, although at first neglected for a few decades and afterwards mistaken for a long time for the similar disorder Hurler syndrome, has been clearly distinguished as a specific disease since 1978, when the distinct genetic causes of the two disorders were finally identified. MPS II is a rare genetic disorder, recently described as presenting an incidence rate ranging from 0.38 to 1.09 per 100,000 live male births, and it is the only X-linked-inherited mucopolysaccharidosis. The complex disease is due to a deficit of the lysosomal hydrolase iduronate 2-sulphatase, which is a crucial enzyme in the stepwise degradation of heparan and dermatan sulphate.
  • Jervis Bay Territory Page 1 of 50 21-Jan-11 Species List for NRM Region (Blank), Jervis Bay Territory

    Jervis Bay Territory Page 1 of 50 21-Jan-11 Species List for NRM Region (Blank), Jervis Bay Territory

    Biodiversity Summary for NRM Regions Species List What is the summary for and where does it come from? This list has been produced by the Department of Sustainability, Environment, Water, Population and Communities (SEWPC) for the Natural Resource Management Spatial Information System. The list was produced using the AustralianAustralian Natural Natural Heritage Heritage Assessment Assessment Tool Tool (ANHAT), which analyses data from a range of plant and animal surveys and collections from across Australia to automatically generate a report for each NRM region. Data sources (Appendix 2) include national and state herbaria, museums, state governments, CSIRO, Birds Australia and a range of surveys conducted by or for DEWHA. For each family of plant and animal covered by ANHAT (Appendix 1), this document gives the number of species in the country and how many of them are found in the region. It also identifies species listed as Vulnerable, Critically Endangered, Endangered or Conservation Dependent under the EPBC Act. A biodiversity summary for this region is also available. For more information please see: www.environment.gov.au/heritage/anhat/index.html Limitations • ANHAT currently contains information on the distribution of over 30,000 Australian taxa. This includes all mammals, birds, reptiles, frogs and fish, 137 families of vascular plants (over 15,000 species) and a range of invertebrate groups. Groups notnot yet yet covered covered in inANHAT ANHAT are notnot included included in in the the list. list. • The data used come from authoritative sources, but they are not perfect. All species names have been confirmed as valid species names, but it is not possible to confirm all species locations.
  • Megalencephaly and Macrocephaly

    Megalencephaly and Macrocephaly

    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
  • Tepzz¥5Z5 8 a T

    Tepzz¥5Z5 8 a T

    (19) TZZ¥Z___T (11) EP 3 505 181 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.07.2019 Bulletin 2019/27 A61K 38/46 (2006.01) C12N 9/16 (2006.01) (21) Application number: 18248241.4 (22) Date of filing: 28.12.2018 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • DICKSON, Patricia GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Torrance, CA California 90502 (US) PL PT RO RS SE SI SK SM TR • CHOU, Tsui-Fen Designated Extension States: Torrance, CA California 90502 (US) BA ME • EKINS, Sean Designated Validation States: Brooklyn, NY New York 11215 (US) KH MA MD TN • KAN, Shih-Hsin Torrance, CA California 90502 (US) (30) Priority: 28.12.2017 US 201762611472 P • LE, Steven 05.04.2018 US 201815946505 Torrance, CA California 90502 (US) • MOEN, Derek R. (71) Applicants: Torrance, CA California 90502 (US) • Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (74) Representative: J A Kemp Torrance, CA 90502 (US) 14 South Square • Phoenix Nest Inc. Gray’s Inn Brooklyn NY 11215 (US) London WC1R 5JJ (GB) (54) PREPARATION OF ENZYME REPLACEMENT THERAPY FOR MUCOPOLYSACCHARIDOSIS IIID (57) The present disclosure relates to compositions for use in a method of treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mu- copolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a re- combinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the en- zymatic activity of the human GNS protein.
  • Comparative Study of Idursulfase Beta and Idursulfase in Vitro and in Vivo

    Comparative Study of Idursulfase Beta and Idursulfase in Vitro and in Vivo

    Journal of Human Genetics (2017) 62, 167–174 OPEN Official journal of the Japan Society of Human Genetics www.nature.com/jhg ORIGINAL ARTICLE Comparative study of idursulfase beta and idursulfase in vitro and in vivo Chihwa Kim1, Jinwook Seo2, Yokyung Chung2, Hyi-Jeong Ji3, Jaehyeon Lee2, Jongmun Sohn2, Byoungju Lee2 and Eui-cheol Jo1 Hunter syndrome is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to the accumulation of glycosaminoglycans (GAGs). Two recombinant enzymes, idursulfase and idursulfase beta are currently available for enzyme replacement therapy for Hunter syndrome. These two enzymes exhibited some differences in various clinical parameters in a recent clinical trial. Regarding the similarities and differences of these enzymes, previous research has characterized their biochemical and physicochemical properties. We compared the in vitro and in vivo efficacy of the two enzymes on patient fibroblasts and mouse model. Two enzymes were taken up into the cell and degraded GAGs accumulated in fibroblasts. In vivo studies of two enzymes revealed similar organ distribution and decreased urinary GAGs excretion. Especially, idursulfase beta exhibited enhanced in vitro efficacy for the lower concentration of treatment, in vivo efficacy in the degradation of tissue GAGs and improvement of bones, and revealed lower anti-drug antibody formation. A biochemical analysis showed that both enzymes show largely a similar glycosylation pattern, but the several peaks were different and quantity of aggregates of idursulfase beta was lower. Journal of Human Genetics (2017) 62, 167–174; doi:10.1038/jhg.2016.133; published online 10 November 2016 INTRODUCTION secreted protein and contains eight N-linked glycosylation sites at Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 309900) positions 31, 115, 144, 246, 280, 325, 513 and 537.
  • Newborn Screening for Mucopolysaccharidosis Type II in Illinois: an Update

    Newborn Screening for Mucopolysaccharidosis Type II in Illinois: an Update

    International Journal of Neonatal Screening Article Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update Barbara K. Burton 1,2,*, Rachel Hickey 1 and Lauren Hitchins 1 1 Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, USA; [email protected] (R.H.); [email protected] (L.H.) 2 Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA * Correspondence: [email protected] Received: 12 August 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare, progressive multisystemic lysosomal storage disorder with significant morbidity and premature mortality. Infants with MPS II develop signs and symptoms of the disorder in the early years of life, yet diagnostic delays are very common. Enzyme replacement therapy is an effective treatment option. It has been shown to prolong survival and improve or stabilize many somatic manifestations of the disorder. Our initial experience with newborn screening in 162,000 infants was previously reported. Here, we update that experience with the findings in 339,269 infants. Measurement of iduronate-2-sulfatase (I2S) activity was performed on dried blood spot samples submitted for other newborn screening disorders. A positive screen was defined as I2S activity less than or equal to 10% of the daily median. In this series, 28 infants had a positive screening test result, and four other infants had a borderline result. Three positive diagnoses of MPS II were established, and 25 were diagnosed as having I2S pseudodeficiency. The natural history and the clinical features of MPS II make it an ideal target for newborn screening.